A midsize speciality pharmaceuticals company has retained Alacrita to conduct a series of due diligence assessments to support its business development function. The client focuses on a particular area defined as disorders of one of the major organ systems and has been very active in licensing and M&A over the past four years.
The client established a framework agreement with Alacrita facilitating the commissioning of a series of due diligence assignments over the course of each year. The typical process involves Alacrita identifying appropriately qualified experts from its network for each DD situation who then interact with the relevant members of the client's internal team. Over the course of any particular year, Alacrita conducts three to five assessments for the client, ranging in size depending on the development stage of the target asset(s).
Alacrita's due diligence consultants have been a trusted source of pharma and biotech DD for over 15 years, underpinned by our ability to ensure each due diligence exercise is supported by individuals with the precise industry expertise required to be thorough, complete and accurate.